{"name":"Abeona Therapeutics","slug":"abeona","ticker":"ABEO","exchange":"NASDAQ","domain":"abeonatherapeutics.com","description":"Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.","hq":"New York, NY","founded":0,"employees":"226","ceo":"Vishwas Seshadri","sector":"Gene Therapy / Rare Disease","stockPrice":4.87,"stockChange":0.06,"stockChangePercent":1.25,"marketCap":"$278M","metrics":{"revenue":12000000,"revenueGrowth":258.2,"grossMargin":0,"rdSpend":26812000,"netIncome":71183000,"cash":191404000,"dividendYield":0,"peRatio":4.8,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"EB-101 patent cliff ($0.00 at risk)","drug":"EB-101","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"AAVDPV patent cliff ($0.00 at risk)","drug":"AAVDPV","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EB-101","genericName":"EB-101","slug":"eb-101","indication":"Cerebral adrenoleukodystrophy (CALD)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ABO-101","genericName":"ABO-101","slug":"abo-101","indication":"Fanconi anemia complementation group C (FA-C)","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"MSI-78","genericName":"MSI-78","slug":"msi-78","indication":"Diabetic foot ulcers with Pseudomonas aeruginosa infection","status":"phase_3"}]}],"pipeline":[{"name":"EB-101","genericName":"EB-101","slug":"eb-101","phase":"phase_3","mechanism":"EB-101 is a gene therapy that delivers a functional copy of the ABCD1 gene to restore adrenoleukodystrophy protein function in patients with cerebral adrenoleukodystrophy.","indications":["Cerebral adrenoleukodystrophy (CALD)"],"catalyst":""},{"name":"ABO-101","genericName":"ABO-101","slug":"abo-101","phase":"phase_2","mechanism":"ABO-101 is a gene therapy that delivers a functional copy of the FANCC gene to correct Fanconi anemia complementation group C deficiency.","indications":["Fanconi anemia complementation group C (FA-C)"],"catalyst":""},{"name":"MSI-78","genericName":"MSI-78","slug":"msi-78","phase":"phase_3","mechanism":"MSI-78 is an antimicrobial peptide that disrupts bacterial cell membranes to treat infections caused by multidrug-resistant pathogens.","indications":["Diabetic foot ulcers with Pseudomonas aeruginosa infection","Multidrug-resistant gram-negative bacterial infections"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Abeona Therapeutics Announces FDA Clearance of IND for EB-101","summary":"Abeona Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for EB-101, its gene therapy for epidermolysis bullosa.","drugName":"EB-101","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Abeona Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Abeona Therapeutics reported its third-quarter 2023 financial results, with a net loss of $13.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Abeona Therapeutics Announces Collaboration with the National Institutes of Health","summary":"Abeona Therapeutics announced a collaboration with the National Institutes of Health to develop gene therapies for rare genetic diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNblYwYU1ILWxmdTF5U2lFTE5oUElvSUQ2UlJLZjRFVkNMbkpVdE4yLUdXbkI3Z0FLYXkwUmVzbVpSVnZ2RVpjTFRXXzJKc0ZHOEhCSGtXOWxIRmhNX0JuS3JQcmdYV3RqNlJ2dWNNQmVwSzFhdkQ1N0RrcXhPd1NMLWd1RTRXVGNUQ1ZfcURNY3J0WHlaYXBQQzdhZ3hPekUxZmJHd0FUV0lXNXZzRW1HYWkwTmJKNFdyeXcwS2Rn?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"Biotech Abeona taps veteran CFO Keith Goldan to oversee audits - Stock Titan","headline":"Biotech Abeona taps veteran CFO Keith Goldan to oversee audits","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPVzFMRFdjS3JQNnV4b1F4MFUyMVZTZmhWaldtNHFlLVJqaWVJYlByLWpaZHQxN1RwdDZySVpkdE5JbWJxRVVDTTZCR0xrb0VlM3Q5YmU2eE9jVnBmMUVJa0JER3BSdEZ3QzRlR0NiQ21hUXFvM1A3RlRwZnJwdkl1bUdkWVZzcGRHdmpRLW9UUkgzaElhZzBDa3FfOGJvV1hWVW5LbDRkQVNQQ3J5a0VRcjRXSFRMV2U2NTRIZjVxNmFzS1UxYzlfQWxBejZaSVJFUXQzV01oUlYyWldDeUpFck9mNnRWTjBCWDcxbnVubEo3SFhLeWc?oc=5","date":"2026-02-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Vanda (VNDA), Abeona Therapeutics (ABEO) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Vanda (VNDA), Abeona Therapeutics (ABEO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNdTBUcnlzZGxDZjExQ0RIcmw3SWVDc1U4QmtxcXVfUDFncVVaSkxVekZtNGJXNS1ickVhRHVZdld0dU5JUkctcXNiVEpobmJUbGNBSGpwc3Y3R29KUjZBbkFEb2p3TE96NUpKWm5RbXRyUzdqLU91bXdla09MdkFod2lPM0E0X1AzS3FOaXA4a2RSZS1HQkszLW1nazMtWk5hOTVwTGZTcHVpR2drMjZQcjVTV3MxRk9fNXc?oc=5","date":"2025-12-15","type":"pipeline","source":"Stock Titan","summary":"Abeona Therapeutics (NASDAQ: ABEO) hires CBO with $5B financing track record - Stock Titan","headline":"Abeona Therapeutics (NASDAQ: ABEO) hires CBO with $5B financing track record","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNa2pCT3d4OV95NmJPX3MtWDgwUjdudWVqbkJ6cXdiNDRXaTFpcTVQX0wwX2xUZ2hIekg0SC0tenFCc1QxYXlqZzR4eUZ6RnRVcFZZZWNMR1VIbzQzMlBfYUVuQm5WZzJBN1l5ak8zRVByNGZ3RjM5cVhsNnk1d0xWUQ?oc=5","date":"2025-08-28","type":"pipeline","source":"NEOtrans","summary":"Abeona Therapeutics to expand in Midtown - NEOtrans","headline":"Abeona Therapeutics to expand in Midtown","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-18","type":"pipeline","source":"simplywall.st","summary":"Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven - simplywall.st","headline":"Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE12LW9ZamtReTgxZ0V1eGxFTU1IbnZLaGNySWplVV9Dc0lhTThheFhhSENTRlZ0RktFSHlLMkw2aVZlZmhkVHZVbWM4N0VBQUw3dkhfRjNWcXdnZ09EakNGTjU1ZU1lLUx6?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Abeona Therapeutics (ABEO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Abeona Therapeutics (ABEO) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-05-01","type":"pipeline","source":"simplywall.st","summary":"Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock increased 22% - simplywall.st","headline":"Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxON3EwSlN4U2FTZ0R1ekZ6SHRkY1kweFZPdnFvbW5fbkJLWlIxNHNfaTJfSk1yUGJJVWFGc00teXd2aHZtRHJ5YnJnMEUyX3BEcHhQWl9ZSFhVTVpqNVV6QzJabDVtdWV1MDIxMndtNzRDVmluY3h5Ukp4SHdjd0UzckdTUjQyVGVfRmtSUTBadnl4NXFwaHE3WENIQ3UyaXJyb2tudHdqVmx3ZFo4OVNuTjVpb3ZRXzBa?oc=5","date":"2025-04-29","type":"regulatory","source":"reuters.com","summary":"US FDA approves first cell-based gene therapy for rare genetic skin disorder - reuters.com","headline":"US FDA approves first cell-based gene therapy for rare genetic skin disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOUXo4NUw2dlRKSHY1WFp5VDMycmppaVJMOUJTeVpUX0h1VXBEQWhsWHFuUXgxYUZieDNUQldIUTk1SDlYTEtjbTRMaTZHbkJkQU1wNU1JNFlBSnNpNzg3SGMzd0dFejFaeVlKVUV5WnFBN0NwNGJNTkp2akxzOFczTHdHWHdaZW5sVjFz?oc=5","date":"2025-04-29","type":"regulatory","source":"Yahoo Finance","summary":"Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy - Yahoo Finance","headline":"Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUGZnT3IwZzJWdER0MHgtWGo2LUtvVmZkdUJET2J5NlJRbmJwYUtxNnpLaUZNMG5CU1RjXzdsNWFvLUJBLVg1SER3LUw5dGphWGM4X1Y3Q3pQeEFNbE5SajEzZjFyM0hEX01XMDRwVkRReWIySHVHRTl0SHByTGJtRVRSSWFfcjhoaXh0a20wZGVVVnR3UVlsY3ZjRHFLQ3B6enh3VGRIc1NCZWpaSFhtUWUyVWpvazAxM19BZnBmYks?oc=5","date":"2025-04-14","type":"regulatory","source":"Seeking Alpha","summary":"Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside - Seeking Alpha","headline":"Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside","sentiment":"neutral"}],"patents":[{"drugName":"EB-101","drugSlug":"eb-101","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"AAVDPV","drugSlug":"aavdpv","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sarepta Therapeutics","BioMarin Pharmaceutical","Pfizer"],"therapeuticFocus":["Gene Therapy","Rare Diseases"],"financials":{"source":"sec_edgar","revenue":2998000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":2998000,"period":"2018-12-31"},{"value":837000,"period":"2017-12-31"},{"value":889000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":26812000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":71183000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":219570000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.87,"previousClose":4.81,"fiftyTwoWeekHigh":7.54,"fiftyTwoWeekLow":3.93,"fiftyTwoWeekRange":"3.93 - 7.54","fiftyDayAverage":4.92,"twoHundredDayAverage":5.47,"beta":1.21,"enterpriseValue":107969800,"forwardPE":20.3,"priceToBook":1.68,"priceToSales":47.69,"enterpriseToRevenue":18.55,"enterpriseToEbitda":-1.24,"pegRatio":0,"ebitda":-86899000,"ebitdaMargin":0,"freeCashflow":-55598500,"operatingCashflow":-76326000,"totalDebt":24968000,"debtToEquity":15.7,"currentRatio":6.93,"returnOnAssets":-34,"returnOnEquity":70,"analystRating":"","recommendationKey":"none","numberOfAnalysts":7,"targetMeanPrice":19.57,"targetHighPrice":28,"targetLowPrice":13,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":15.7,"institutionHeldPercent":69.5,"sharesOutstanding":57049023,"floatShares":42548302,"sharesShort":15098544,"shortRatio":15.17,"shortPercentOfFloat":26.5,"epsTrailing":1.01,"epsForward":0.24,"revenuePerShare":0.11,"bookValue":2.89,"officers":[{"age":48,"name":"Dr. Vishwas  Seshadri M.B.A., Ph.D.","title":"President, CEO & Director"},{"age":40,"name":"Mr. Joseph Walter Vazzano CPA","title":"Chief Financial Officer"},{"age":56,"name":"Dr. Brendan M. O'Malley J.D., Ph.D.","title":"Chief Legal Officer"},{"age":null,"name":"Mr. Brian  Kevany Ph.D.","title":"Chief Technical & Scientific Officer"},{"age":null,"name":"Mr. Gregory  Gin","title":"Vice President of Investor Relations & Corporate Communications"},{"age":65,"name":"Mr. Jon  Voss","title":"VP & Head of Quality"},{"age":null,"name":"Dr. Madhav  Vasanthavada M.B.A., Ph.D.","title":"Chief Commercial Officer"},{"age":null,"name":"Mr. Carl  Denny","title":"Senior Vice President of Regulatory Affairs"}],"industry":"Biotechnology","irWebsite":"http://www.accesspharma.com/investor-relations/","website":"https://www.abeonatherapeutics.com","phone":"646 813 4701"}}